Abstract:

Objective     To observe efficacy and safety of combined sodium ozagrel with low molecular weight heparin on patients with progressive cerebral infarction. Methods    112 cases of progressive cerebral infarction were randomly divided into the treatment group (56 cases) and the control group (56 cases). The control group was only administered 80mg of sodium ozagrel, bid, for 14 days. And the treatment group was administered 80mg of sodium ozagrel, bid, for 14 days and 0.4mL of low molecular weight heparin sodium injection, bid, for 14 days. The therapeutic effect was evaluated by the National Institutes of Health Stroke Scale (NIHSS) and the Bathal index (BI). Liver and renal function, blood and urinary routines, blood clotting routine and electrocardiogram (ECG) were detected before and after 14 days of treatment. Results     Compared with the control group, grades of NIHSS and BI in the treatment group were significantly lower after one (P<0.05) and two weeks (P<0.01). Both the number of platelets and blood coagulation time were within the normal range. There was no obvious side effect in either groups. Conclusion     Sodium ozagrel combined with low molecular weight heparin is an effective and safe therapy for progressive cerebral infarction.

Key words: Tedelparin; Brain infarction; Treatment out come;  Sodium ozagrel